In PYC's recent webinar, (30th May), it was mentioned that the focus of commercial discussions has changed somewhat. Back in time, apparently the interest coming to PYC was mainly about our early individual pipeline assets, it would appear we are now gaining legitimate interest for our entire platform. And it would seem PYC have good reason to think a platform deal may be the way to go.
A slide was included in that webinar,
Maximizing value... knowing when NOT to sell or partner.
RH openly said, the best time to talk about deals is once they are done and hence he expressed little interest to say too much more. So why include that slide? I conclude that the information in that slide makes a strong case for NOT selling or partnering an early stage asset as it may work against the bigger picture of getting a cracking hot platform deal a bit further down the track.
We know, safety and efficacy are regarded as 'the currency' in PYC's world, so if we believe in the potential for more in-pipeline clinical successes, it's not hard to fathom that the value of our platform is further de-risked with each clinical step forward, which leads me to think those clinical steps may individually and collectively have a very positive impact on deal $dollars for anyone wishing to sit at the PYC platform table.
PYC announced this week their intention to initiate clinical in-human studies for PMS, starting in approximately 12 months from now, however a massive amount of data to support this initiative has been garnered already.
Long story, shortened, PYC presented at...
CureSHANK, 2nd Annual Phelan-McDermid Syndrome Drug Development Symposium on Friday 27th June, Spain time. See below..
Segment for - Noncommercial & Commercial Clinical Trials and Business considerations.
3 x 10m speakers & 3 x 15min speakers with Q & A after
11:50 – 12:05
PYC SHANK3 ASO
Janya Grainok, PhD
Chief Discovery Officer, PYC Therapeutics, Perth, Australia
(from PYC's ASX announcement)...
PYC presented data that demonstrates that PYC-002 restores the missing gene
expression that causes PMS in brain cells derived from patients and rescues the
functional deficits in these neurons that underlie the neurodevelopmental delays that
characterise the syndrome. In addition, PYC will also be presenting in vivo data for its clinical
candidate demonstrating effective control of target gene expression in the key regions of
the brain implicated in PMS.
One thing about PYC that has stuck in my mind, is that they really strive for excellence and aim to be the best in their class of endeavour. I truly believe that PYC have spent considerable time and effort to ensure that their revised pathway for PMS will align with their consistently high standards. Time will tell, so I will let that idea rest for now however I must say targeting neurological diseases is a BIG Door for PYC to go after. My interest is truly lit up.
Now, circling back to Platform interest discussions and other possible relevant drivers...
RP11 120mcg doses may potentially be included in the registrational trial, subject to safety data, due fairly soon. Expanded dosing interval for patients? and maybe we will see an uptick in efficacy, I am not suggesting a linear correlation but an efficacy uptick of some degree could reasonably emerge. And I certainly don't rule the possibility that PYC may apply for an Accelerated pathway for RP11, especially if the quality of our data keeps improving as ongoing dosing studies extend and more patients are hitting dose participation inclusion periods. IE 12mth, 18mth etc.
The recent Cap Raise, provides PYC the funding to take RP11 all the way, we are not desperate and dateless!
PKD, a blockbuster target for sure... lot's to like here, but need to put a limit to this post. The needle may be moving fasterfor PKD than many think.
ADOA back on track and confidence remains rock solid, won't be long for more data to come forward.
Ai, in addition to PYC's early pipeline candidates, I believe we likely have a long list of potential fast followers identified through this highly strategic endeavour. Possibly an appetite stimulus for platform deal $dollars.
In summary, I think there is massive conceptional value within a basket that embraces a platform deal and we seem to be ticking the right boxes.
Expand
